Blue Jay Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Blue Jay Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-175,000	Closed	-$10.3M	–	24
2015 Q2	$10.3M	Sell	175,000 -30,000	-15%	-$1.85M	2.78%	21
2015 Q1	$12.8M	Buy	205,000 +25,000	+14%	+$1.45M	4.48%	13
2014 Q4	$10.4M	Buy	+180,000	New	+$10M	4.62%	9

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Blue Jay Capital Management's TEVA Position: Q3 2015 in Review

Blue Jay Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2015, closing a stake of 175,000 shares — an estimated $10.3M sold.

Blue Jay Capital Management first reported a position in TEVA in Q4 2014 and held it in 3 quarters. The position peaked at $12.8M in Q1 2015. 824 funds tracked by Wall St. Rank hold TEVA as of Q3 2015.

Blue Jay Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Blue Jay Capital Management sold 175,000 Teva Pharmaceuticals shares in Q3 2015, an estimated $10.3M.
Blue Jay Capital Management first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 3 quarters.
Blue Jay Capital Management's Teva Pharmaceuticals position peaked at $12.8M in Q1 2015.
824 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2015.

Based on Blue Jay Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.